Articles By Cyndi Root

51. New and Updated Drug Shortages List 11/10/14 11/13/2014

    The Food and Drug Administration (FDA) has published its new and updated Drug Shortages through 11/10/14.

52. Asia-Based CRO GVK BIO Acquires CRO Vanta Bioscience 11/12/2014

    GVK BIO has acquired Vanta Bioscience in a deal that brings Vanta’s GLP toxicology capabilities into GVK’s service offerings. The Vanta Acquisition was announced in a press release, stating that the move is advantageous to both contract research organizations (CROs).

53. Baxter Builds Bigger Admixing Facility For Canadian Market 11/11/2014

    Baxter continues to expand its pharmaceutical manufacturing efforts, investing $10 million for a bigger admixing facility to serve the Canadian market.

54. Astellas, Dana-Farber Cancer Institute To Study Oncogenic K-Ras Inhibitors 11/9/2014

    Astellas Pharma intends to conduct oncology treatment studies with the Dana-Farber Cancer Institute.

55. Takeda, Intra-Cellular Therapies Terminate PDE1 Inhibitors Collaboration 11/7/2014

    Takeda Pharmaceutical Company and Intra-Cellular Therapies have agreed to terminate their partnership on Intra-Cellular’s ITI-214 and related PDE 1 inhibitors.

56. WuXi AppTec Opens Israel Office, Partners With Pontifax 11/6/2014

    WuXi AppTec, a contract research organization (CRO), has opened an office in Israel and partnered with Pontifax to develop Israeli biotechnology.

57. Weekly FDA Enforcement Report For Drugs 10/29/14 11/5/2014

    The Food and Drug Administration (FDA) has released its Drug product Enforcement Report for October 29, 2014.

58. CDMO Lonza And Bristol-Myers Squibb Expand Manufacturing Agreement 11/4/2014

    Bristol-Myers Squibb (BMS) continues to focus on biologics manufacturing and has extended its manufacturing agreement with Lonza, a contract development and manufacturing organization (CDMO), based in Visp, Switzerland. BMS announced the multi-year contract expansion in a news release, stating that Lonza’s facility in Portsmouth, New Hampshire will produce commercial quantities of a biologic medicine.

59. Medivation Licenses Pidilizumab, Oncology Monoclonal Antibody From CureTech 10/29/2014

    Medivation has licensed an oncology treatment, pidilizumab (CT-011), from CureTech, an Israeli company.

60. Rhythm, Actavis Partner On Relamorelin For GI Disorders 10/28/2014

    Actavis and Rhythm have struck a deal wherein Actavis will co-develop relamorelin (RM-131) for gastrointestinal (GI) disorders and have the option to buy Rhythm’s subsidiary, Rhythm Health, which is developing relamorelin.